



Anesthesia  
Patient Safety  
Foundation

# Medication Safety: Pre-Filled Syringes, Drug Labeling, and Infusion Pumps



Elizabeth Rebello, MD, FASA, CPPS, CMQ  
APSF Board Member  
Professor, Dept. of Anesthesiology & Perioperative Medicine  
UT MD Anderson Cancer Center

2022 APSF Stoelting Conference  
Wednesday, September 7, 2022

# Objectives

---



**Identify the differences between feedback and constraints in the perioperative environment**



**Analyze the multi factorial issues involving the labeling of syringes and vials in the perioperative environment and beyond**



**Develop a working knowledge regarding Smartpumps and DERS**

# Criminalization of Medical Error

December  
2017

- RN Vaught administered vecuronium in place of midazolam in a NORA suite resulting in the death of 75 year-old patient Charlene Murphey


March 2022

- Vaught convicted of gross neglect of an impaired adult and negligent homicide

May 2022

- Vaught sentenced to three years' probation

<https://www.apsf.org/news-updates/position-statement-on-criminalization-of-medical-error-and-call-for-action-to-prevent-patient-harm-from-error/#:~:text=APSF%20believes%20that%20the%20criminal,prosecution%20of%20individual%20healthcare%20professionals.>  
[https://en.wikipedia.org/wiki/RaDonda\\_Vaught\\_homicide\\_case](https://en.wikipedia.org/wiki/RaDonda_Vaught_homicide_case)



# Criminalization of Medical Error



## Position Statement on Criminalization of Medical Error and Call for Action to Prevent Patient Harm from Error

May 25, 2022

### Executive Summary

Preventable harm from the systems of care intended to improve health continues to occur at an unacceptable rate in the United States. Our hearts go out to patients, families, and caregivers who have suffered preventable harm related to health care. Healthcare systems have an opportunity to learn and improve from each episode of preventable harm. Accordingly, every preventable patient death or injury must energize our efforts to prevent future patient harm. APSF believes that the criminal prosecution of healthcare professionals will make the work of preventing harm more difficult by shifting the focus from needed system improvements. This position statement outlines the rationale for opposing criminal prosecution of individual healthcare professionals. It recommends that all healthcare systems and organizations aggressively act now to improve their cultures, processes, and training to reduce errors of all kinds and, specifically considering recent events, medication errors. Some specific actions are recommended as examples of actionable steps. Additionally, individual healthcare professionals are encouraged to be mindful of their role in preventing errors, and reporting errors that occur and to collaborate with their organizations to proactively identify and improve the flaws in the systems in which they work that lead to preventable patient harm.

**“APSF believes that the criminal prosecution of healthcare professionals will make the work of preventing harm more difficult by shifting the focus from needed system improvements.”**

# Medication Safety and NORA



## Medication safety in nonoperating room anesthesiology

Patricia Fogarty Mack

### Purpose of review

Medication errors remain a prominent source of medical harm in spite of over 20 years of effort in establishing standardized protocols and procedures, implementing assistive electronic technologies to identify medications and prevent administration errors and in establishing a just culture with regard to reporting events and near misses.

### Recent findings

Some of these interventions are even more necessary in the nonstandard environment of a non-operating room anesthesiology (NORA) procedure suite, where the anesthesiologist is often far removed from colleagues, in a dark room, lacking the standard medications commonly found in their operating room. Medication availability in NORA sites may be limited because of lack of standardization or distance from the operating room pharmacy. Proper preparation of medication may be impaired by poor lighting and cramped conditions. Medication administration might be hampered by a lack of infusion pumps or pumps without the proper medication library needed by the anesthesiologist.

### Summary

Specific attention must be paid to enhancement of medication safety in NORA sites to overcome additional challenges inherent in the provision of anesthesia care remote from the standard operating room setting.

### Keywords

collaboration and communication, environment of care, standardization of medications, technological advancements for safety

- Distant location
- Limited availability of medications/supplies
- Physical and lighting limitations
- Challenges in monitoring
- Lack of familiarity with procedures and medications

## Safety of Non-Operating Room Anesthesia A Closed Claims Update



Zachary G. Woodward, MD<sup>a</sup>,  
Richard D. Urman, MD, MBA, FASA<sup>a,b,\*</sup>, Karen B. Domino, MD, MPH<sup>c</sup>

### KEYWORDS

• Closed claims • Non-operating room anesthesia (NORA) • Remote anesthesia  
• Gastroenterology • Cardiology • Radiology • Sedation • Medical malpractice

### KEY POINTS

- Malpractice claims for non-operating room anesthesia care (NORA) had a higher proportion of claims for death compared with operating room (OR) settings.
- Aspiration pneumonia occurred in a higher proportion of NORA malpractice claims, compared with claims in OR settings.
- NORA claims most frequently involved monitored anesthesia care. Inadequate oxygenation/ventilation was responsible for nearly one-third of NORA claims.
- Malpractice claims for NORA were less frequent than claims for OR anesthesia as assessed by the number of anesthetics in NORA versus OR locations.
- NORA claims occurred more frequently in cardiology and radiology locations compared with the number of anesthetics in these procedural locations, suggesting a higher risk of adverse events in these locations.

**Closed Claims (2002-2012): higher proportion of malpractice claims for death in NORA settings than in operating room settings**

**NORA Medication-related Claims: 6 %**



# Medication Errors

- Frequency of medication errors in the perioperative environment: 1 out of 20 administrations
- Observed error rates are higher than self-reported rates
- Types of Errors: 1) incorrect dosing  
2) substitution  
3) contraindicated drug administration  
4) timing errors

# Phases of Medication Process

SENSAR: 1970 MRE/7072  
(28%) incidents

**Administration phase  
most frequent (42%) and  
highest harm**

Phase of medication process	1970	
Administration	835 (42)	Unintended epidural fentanyl administration instead of intravenous.
Prescription	425 (22)	Amoxicillin regimen prescription in a penicillin allergic patient.
Preparation	258 (13)	Incorrect epinephrine concentration labelling.
Dispensation	206 (11)	Incorrect medication (atropine vs adrenaline) given from one provider to the medication administering provider.
Monitoring	80 (4)	Absence of coagulation test in a patient under oral anticoagulant treatment.
Others	166 (8)	Preoperative medication administered is not registered in the clinical documentation of the patient, only oral information is recorded.
Type of MREs	1970	
Wrong treatment regimen	544 (28)	Continuous local epidural anaesthetic perfusion to 60 ml h <sup>-1</sup> instead of 6 ml h <sup>-1</sup> .
Wrong medication	534 (27)	Ceftazidime administration instead of the cefazolin prescribed.
No administration	184 (9)	Inadvertent loss of intravenous access during general anaesthesia, with a total intravenous anaesthesia impossible administration.
Wrong route of administration	112 (6)	Enteral nutrition connected to central intravenous access.
Wrong dosage	110 (6)	1000 µg ml <sup>-1</sup> phenylephrine inadvertent administration instead of 100 µg ml <sup>-1</sup> , with patient extreme bradycardia.
Expired medication	17 (1)	Expired epidural local anaesthetic bags storage in refrigerator.
Others	469 (24)	Anaphylaxis with amoxicillin.
Medication group involved	1970	
Medications that alter haemostasis	359 (18)	Low molecular weight heparin, sodium heparin, acetylsalicylic acid, acenocoumarin, protamine, clopidogrel, tranexamic, phyto methadione.
Vasconstrictor agents	253 (13)	Atropine, noradrenaline, phenylephrine, adrenaline, ephedrine, dopamine, isoproterenol.
Opiates	204 (10)	Remifentanyl, morphine chloride, fentanyl, tramadol, methadone, sufentanil, alfentanil, meperidine.
Antimicrobial agents	163 (8)	Vancomycin, cefazolin, amoxicillin, clindamycin, gentamicin, teicoplanin, meropenem, ciprofloxacin.
Local anaesthetics	137 (7)	Bupivacaine, lidocaine, ropivacaine, levobupivacaine, mepivacaine, prilocaine.
Inhalation/intravenous anaesthetics	103 (5)	Sevoflurane, protoxide, desflurane, propofol, etomidate, dexmedetomidine, ketamine, thiopental.
Neuromuscular blocking agents	97 (5)	Rocuronium, cisatracurium, succinylcholine, atracurium.
Minor analgesics	93 (5)	Metamizole, dextetopfen, paracetamol, diclofenac.
Reversal agents/antidotes	67 (3)	Sugammadex, neostigmine, flumazenil, naloxone.

# Anesthesia Safety Tools

Left (Medication) Side	Right (Machine) Side
<b>No</b> Dose Checking	Color-Coded Gases / Lines
<b>No</b> Alarms	Diameter and Pin-Index Safety Systems
<b>No</b> Way to Detect Errors	Oxygen-Nitrous Coupler
<b>No</b> “Exhaled” Propofol Monitor	Gas Monitors and Alarms
	Pressure and Flow Sensors and Alarms
	Keyed and Colored Vaporizer Fillers
	Patient Monitors: SpO <sub>2</sub> , ETCO <sub>2</sub>
	Flow Meter Assembly Order
	Oxygen Pressure Failure Device
	Vaporizer Transport Setting
	Machine Check

Grigg and Roesler. Anesth Analg 126(1): 346-50, 2018.



# Feedback vs. Constraints

Feedback	Constraints
Color-coded syringes*	Smart pump guardrails
Barcode scanners	Standard pharmacy concentrations
Labels	Prefilled syringes
Two-provider checks / Checklists	Standard layouts
Alarms	(Machine examples...)



30442240

- Feedback requires compliance and engagement

# Constraints

## Eliminate steps / options


- Automate processes
- Physically prevent mistakes
- Types
  - Interfaces (pin-index, filler keys)
  - Coupling (O2-nitrous)
  - Standardization



Without impacting workflow / decision-making

# Failure Mode and Effects Analysis

- Failure Mode and Effects Analysis
- 5 steps
- 18 sub-steps (blue)
- 68 possible failure modes (yellow)
- Prefilled Syringes
- 6 sub steps eliminated
- 19 possible failure modes eliminated



# Labeling



## Statement on Labeling of Pharmaceuticals Used in the Practice of Anesthesiology

Committee of Origin: Equipment and Facilities

(Approved by the ASA House of Delegates on October 27, 2004, and last amended on December 13, 2020)

**Statement:** The primary consideration for the design and use of labels for syringes, drug infusion bags, and medication containers should be the reduction of medication errors and thus safer patient care. This is particularly true for the potent medications used in the practice of anesthesiology. Therefore, the ASA supports the manufacture and use of labels that meet the standards described below, which are consistent with those established by ASTM International (formerly the American Society for Testing and Materials), the International Organization for Standards (ISO), as well as recommendations and guidelines from the Food and Drug Administration (FDA) and the Institute



Figure 1:



Reprinted with permission from Fresenius Kabi.

Figure 2:



Reprinted with permission from Fresenius Kabi.

apsf APSF @APSEorg · 1/17/19

APSF would like to get your preference on syringe labeling. Which do you prefer to indicate dosing on a syringe?

#anesthesia #medicationsafety #lookalikevals

3mg per 3ml (1mg per ml)	5%
1mg per ml; 3 mg per 3ml	7%
3 mg per 3ml (1 mg/ml)	20%
1 mg/ml; 3mg per 3ml	68%

417 votes · Final results

16 34 29

<https://www.asahq.org/standards-and-guidelines/statement-on-labeling-of-pharmaceuticals-for-use-in-anesthesiology>



# USP

## ⟨7⟩ LABELING

### DEFINITION

The term *labeling* designates all labels and other written, printed, or graphic matter on an article's immediate container or on, or in, any package or wrapper in which it is enclosed, except any outer shipping container. The term *label* designates that part of the labeling on the immediate container.

A shipping container that contains a single article, unless the container also is essentially the immediate container or the outside of the consumer package, must be labeled with a minimum of product identification (except for controlled articles), lot number, expiration date, and conditions for storage and distribution.

### LABELS AND LABELING FOR DRUG PRODUCTS EXPRESSED AS ACTIVE MOIETY IN NAME AND STRENGTH

The names and strengths of drug products and compounded preparations shall be expressed in terms of the active moiety and its corresponding strength on the label (see *Nomenclature* (1121), *Monograph Naming Policy for Salt Drug Substances in Drug Products and Compounded Preparations*).

**Exceptions:** In those rare cases in which the use of the specific salt form of the active moiety in the title provides vital information from a clinical perspective, an exception to this Policy may be considered. In such cases, where the monograph title contains the specific salt form of the active moiety, the strength of the product or preparation is also expressed in terms of the specific salt form.

**Labeling:** The labels and labeling shall clearly state the specific salt form of the active moiety that is present in the product/preparation, as this information may be useful to practitioners and patients. The names and strengths of both the active moiety and specific salt form (where applicable) are provided in the labeling.

### LABELS AND LABELING FOR INJECTABLE PRODUCTS

and/or drug substance in a large-volume injection (LVI), the concentration of each active moiety and/or drug substance named in the official title is stated as if it were part of the official title (e.g., *5% Dextrose Injection*, or *5% Dextrose* and *0.2% Sodium Chloride Injection*).

Injections that are intended for veterinary use only should be labeled to that effect.

Vaccine labeling is not included in this general chapter.

### Strength and Total Volume for Single- and Multiple-Dose Injectable Drug Products

For single- and multiple-dose injectable drug products, the strength per total volume should be the primary and prominent expression on the principal display panel of the label, followed in close proximity by strength/mL enclosed by parentheses. For containers that hold a volume of less than 1 mL, the strength per fraction of a mL should be the only expression of strength. Strength per single mL should be expressed as mg/mL, not mg/1 mL. The following formats are acceptable for contents greater than 1 mL:

Total strength/total volume: 500 mg/10 mL

Strength/mL: 50 mg/mL

or

Total strength/total volume: 25,000 Units/5 mL

Strength/mL: 5000 Units/mL

The following format is acceptable for contents less than 1 mL:

12.5 mg/0.625 mL

There are some exceptions to expressing strength per total volume. In certain cases, the primary and prominent expression of the total drug content per container would not be effective in preventing medication errors (e.g., insulin). Another example is the use of lidocaine (or similar drugs for local anesthesia where the product is ordered and administered by percentage (e.g., 1% or 2%). In such cases, the total strength should be expressed: for example, 1% can be expressed as

(100 mg/10 mL) or

(10 mg/mL).

Dry solids that must be reconstituted should follow the same format with the exception that only the total strength of the








# Infusion Pumps

- From 2002-2009, 56,000 adverse events and numerous deaths associated with infusion devices
- Smart infusion pumps are intended to ensure safe intravenous medication use by preventing over and under dosing
- REMEDI project was initiated in response to the national priority to improve patient safety for infusion pumps and to a request from the Indianapolis Coalition for Patient Safety



# REMEDI database

"To be a vibrant, resourceful and collaborative community that advances and promotes infusion pump medication administration in the interest of patient safety and quality."



Regenstrief National Center for Medical Device Informatics (REMEDI)

<https://www.purdue.edu/discoverypark/rche/REMEDI/REMEDI%20Overview.php>

[https://www.fda.gov/medical-devices/general-hospital-devices-and-supplies/infusion-pumps?\\_ga=2.51818473.158693613.1643124592-1816386686.1643124592](https://www.fda.gov/medical-devices/general-hospital-devices-and-supplies/infusion-pumps?_ga=2.51818473.158693613.1643124592-1816386686.1643124592)

## REMEDI

[Medical Device Informatics Overview](#)[Awards](#)[Events](#)[Members](#)[Join REMEDI](#)[REMEDI Research](#)

## REMEDI Research

Researchers at Purdue University – and beyond – leverage the data and the community to improve patient and medication safety.

### A representative sample of our publications

- DeLaurentis, Poching, Kang-Yu Hsu, and Yuval Bitan (2018). **Prevalence of wireless smart-pump drug library update delays**. *American Journal of Health-System Pharmacy*. June 2018. <https://doi.org/10.2146/ajhp170824>.
- Harris, P.R., S. Strickland, R. Zink, M.N. Flack, AAMI Ventilator Alarms Workgroup (2018). **The Mechanical Ventilator Alarm Default Setting Project**. *American Thoracic Society 2018 International Conference: Poster Session B53: Enhancing Practice Environments, Patient Safety, and Outcomes*. May 2018.
- Yu, Denny, Kang-Yu Hsu, Joon Hong Kim, and Poching DeLaurentis (2017). **Infusion pump informatics approach to quantify impact of alerts and alarms on healthcare delivery**. *Proceedings of the Human Factors and Ergonomics Society Annual Meeting*. Vol 61, Issue 1, pp. 681-685. September 2017. <https://doi.org/10.1177%2F1541931213601657>.
- Giuliano, Karen, Wan-Ting Su, Daniel Degnan, Kristy Fitzgerald, Richard Zink, and Poching DeLaurentis (2017). **Intravenous Smart Pump Drug Library Compliance: A Descriptive Study of 44 Hospitals**. *Journal of Patient Safety*. June 2017. <https://doi.org/10.1087/BTS.0000000000000383>

# Team Effort

- Local facilities may seek to harmonize such concentrations with pharmacy services and other stakeholders and within their drug libraries
- Balance the objective of reducing the risk of patient harm with pragmatic considerations, such as strength and quality of evidence, feasibility and economic burden



# Key Takeaways

---

- Utilize Constraints when available
  - Prefilled syringes, standardization, SMART pumps
- Understand the increased risk of the NORA environment
- Maintain vigilance







## Patient Safety Resources

COVID Perioperative Resource Center

Anesthesia Patient Safety Podcast

APSF Video Library

News & Updates

In the Literature

Look-Alike Drug Vials

Innovative Reports and Ideas

Drug-Drug Interactions (DDI)

Emergency Manuals Implementation  
Collaborative

## LOOK-ALIKE DRUG VIALS: LATEST STORIES & GALLERY



The following alerts and photos show how look-alike drug vials and packaging can contribute to medication errors and impact patient safety.

### QUICKLINKS:

- [Latest Alerts](#)
- [Look-Alike Drug Vials Gallery](#)
- [APSF Articles and Media](#)
- [Submit a Look-Alike Drug Alert](#)

## Latest Alerts

### Phenylephrine Hydrochloride Injection, Neostigmine Methylsulfate Injection

June 3, 2022

Concentrated phenylephrine and neostigmine vials and color schemes nearly identical.



Submitted by  
Christopher Seiter, DO  
Stony Brook Medicine



Phenylephrine Hydrochloride Injection, Neostigmine Methylsulfate Injection



# Medication Safety Begins with YOU!



[erebello@mdanderson.org](mailto:erebello@mdanderson.org)

@ERebelloMD